Notably, therapies directed at these pathways have demonstrated success in treating diseases such as psoriasis, psoriatic arthritis and Crohn’s disease (38, 39), owing to the similarly shared IL-17/IL-23 signaling pathways from among these conditions. This evidence concerns the gene IL17A and psoriasis.